| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbd5a982e9858f1f9ffc463b6ce69d7b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4174
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-02 |
| filingDate |
1997-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2b99b24362a757a6b4812a4b2fb0794
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c88f119b1406e160b0ba7a42162778a |
| publicationDate |
2002-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2195281-C2 |
| titleOfInvention |
Antivaginitis composition for topical application comprising one or more antivaginitis medicinal agents and one or more topical anesthetics |
| abstract |
FIELD: medicine, gynecology, pharmacy. SUBSTANCE: pharmaceutical composition for topical application used for vaginitis treatment comprises metronidazole and myconazole as medicinal agents and topical anesthetic lidocaine in form providing delayed (prolonged) release of drugs. Composition is made as cream or pessary. Myconazole can be used as saline form - myconazole nitrate. Topical anesthetic lidocaine can be used both as a free base and salt. Application of combination of metronidazole and myconazole with anesthetic lidocaine eliminates morbid sensations caused by vaginitis in the simultaneous decrease or elimination of irritation as burning. EFFECT: enhanced effectiveness of composition, valuable medicinal properties. 11 cl, 10 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-011952-B1 |
| priorityDate |
1996-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |